Adial Pharmaceuticals Reaches Full Enrollment Target for ONWARD(TM) Phase 3 Trial of AD04 for the Treatment of Patients With Alcohol Use Disorder

Stock Information for Adial Pharmaceuticals Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Adial Pharmaceuticals Inc

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office
Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20
Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office
Adial Announces Appointment of Tony Goodman as Chief Operating Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.